Quinoline-derived amide modulators of vanilloid VR1 receptor
申请人:——
公开号:US20040192728A1
公开(公告)日:2004-09-30
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR
申请人:Codd Ellen
公开号:US20080300236A1
公开(公告)日:2008-12-04
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
[EN] QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR<br/>[FR] AMIDES DERIVES QUINOLINIQUES MODULANT LE RECEPTEUR VR1 VANILLOIDE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2004069792A2
公开(公告)日:2004-08-19
This invention is directed to vanilloid receptor VR1 ligands of formula (I). More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
Biaryl derived amide modulators of vanilloid VR1 receptor
申请人:Codd Ellen
公开号:US20060223837A1
公开(公告)日:2006-10-05
The invention is directed to novel vanilloid receptor type 1 (VR1) ligands. More specifically, the invention relates to novel biaryl-derived amides that are potent antagonists or agonists of VR1. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.